Human CD106 Recombinant (VCAM1)

HomeSurface & Soluble Receptors

Human CD106 Recombinant (VCAM1)

$160.00 – $1,950.00

SKU: RKP19320 Category: Surface & Soluble Receptors Tags: CD antigen CD106, INCAM-100, P19320, V-CAM 1, VCAM-1, VCAM1

Description

Methods (1)


accession	P19320

Source	Optimized DNA sequence encoding Human extracellular domain of human CD106including a C-terminal 6His tag was expressed in HEK293 cells.
Molecular weight	Recombinant CD106 (VCAM1) is a monomer protein consisting of689 amino acid residue subunits,due to glycosylation migrates as an approximately110 kDa protein on SDS-PAGE.
Purity	>95%, as determined by SDS-PAGE and HPLC
Biological Activity	The activity of recombinant VCAM1 was tested by immobilized recombinant CD106 (10ug/ml) ability to support adhesion of U937 human histiocytic lymphoma cells (5x104 cells/well ) , 70% will adhere after 60min at 37C.
Endotoxin	Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg(1EU/µg).
Presentation	Recombinant CD106is supplied as a 0.2 μm filtered PBS solution, pH7.2 .
Storage	Recombinant CD106, as supplied, can be stored in working aliquots at 2° - 8° C for one month, or at -20°C to-70°Cfor twelve months. Avoid repeated freeze/thaw cycles.
Usage	This product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.

Biological Process	Cell-adhesion
Biological Process	Host-virus-interaction

Methods


Flow cytometry and Western analysis surface expression was evaluated by staining with phycoerythrin (PE)-conjugated anti-VCAM-1 (eBioscience, 12-1069-41), goat polyclonal anti-IL13α2 AF146 followed by detection with PE-conjugated donkey anti-goat , PE-conjugated mouse monoclonal anti-IL13α2 B-13 ( lots 1107403, 1107404 and 1107405), or unconjugated B-13 antibodies ( and ) followed by detection with PE-conjugated goat anti-mouse ( Immunoesearch). In some cases B-13 reagent was first pre-incubated for thirty minutes with soluble recombinant human IL13α2-Fc chimera or VCAM-1/C106-Fc chimera reagents . Percentages of positively staining cells were calculated using the subtraction method with FCS Express version 3 software . Relative fluorescence intensity was calculated by dividing the MFI experimental by the MFI of the control. IL-13 biotin binding assays were done by biotinylating IL-13 at a 2.5 biotin to recombinant IL-13 ratio using the EZ-Link Sulfo-NHS-Biotin kit as per the manufacturer's instructions. The biotinylated IL-13 was then incubated with various glioma lines, followed by staining with surface expression was evaluated by staining with phycoerythrin (PE)-conjugated anti-VCAM-1 (eBioscience, 12-1069-41), goat polyclonal anti-IL13α2 AF146 followed by detection with PE-conjugated donkey anti-goat , PE-conjugated mouse monoclonal anti-IL13α2 B-13 ( lots 1107403, 1107404 and 1107405), or unconjugated B-13 antibodies ( and ) followed by detection with PE-conjugated goat anti-mouse ( Immunoesearch). In some cases B-13 reagent was first pre-incubated for thirty minutes with soluble recombinant human IL13α2-Fc chimera or VCAM-1/C106-Fc chimera reagents . Percentages of positively staining cells were calculated using the subtraction method with FCS Express version 3 software . Relative fluorescence intensity was calculated by dividing the MFI experimental by the MFI of the control. IL-13 biotin binding assays were done by biotinylating IL-13 at a 2.5 biotin to recombinant IL-13 ratio using the EZ-Link Sulfo-NHS-Biotin kit as per the manufacturer's instructions. The biotinylated IL-13 was then incubated with various glioma lines, followed by staining with streptavidin-PE. Read more